What is it about?
Metrinomic therapy is underevaluated in lung cancer. Oral drugs like vinorelbine allow continous daily dosing in an outpatient setting. We established a recommended dose and showed preliminary efficacy in heavily pretreated patients with NSCLC
Featured Image
Why is it important?
Metronomic application of daily oral vinorelbine offers a further treatment options in advanced pretreated patients with NSCLC
Perspectives
Metronomic oral daily application allows variable and adjusted tretment. It could also be integrated in simultaneous radiochemotherapy schedules.
Professor Rudolf M. Huber
University of Munich and Thoracic Oncology Centre Munich
Read the Original
This page is a summary of: Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine – a Phase I trial, OncoTargets and Therapy, February 2017, Dove Medical Press,
DOI: 10.2147/ott.s122106.
You can read the full text:
Contributors
The following have contributed to this page
